Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

Show other versions (1)

Bibliographic Details
Main Authors:	Cheng, Z, Gong, Y, Ma, Y, Lu, K, Lu, X, Pierce, L, Thompson, R, Muller, S, Knapp, S, Wang, J
Format:	Journal article
Published:	2013

Similar Items

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
by: Cheng, Z, et al.
Published: (2013)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Discovery of BET bromodomain inhibitors and their role in target validation
by: Mueller, S, et al.
Published: (2014)

Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013)

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
by: Delmore, Jake E., et al.
Published: (2014)

Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Filippakopoulos, P, et al.
Published: (2012)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
by: Wendy Mao, et al.
Published: (2019-10-01)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
by: Flore Mietton, et al.
Published: (2017-05-01)

Interactome rewiring following pharmacological targeting of BET bromodomains
by: Lambert, J-P, et al.
Published: (2018)

Bromodomains as therapeutic targets.
by: Muller, S, et al.
Published: (2011)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
by: Vittoria Graziani, et al.
Published: (2023-01-01)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
by: Shumei Song, et al.
Published: (2020-06-01)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2017-01-01)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Irawati Kandela, et al.
Published: (2015-06-01)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
by: Picaud, S, et al.
Published: (2013)

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2018-01-01)

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
by: Sergey Karakashev, et al.
Published: (2017-12-01)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
by: Picaud, S, et al.
Published: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
by: Picaud, S, et al.
Published: (2013)

BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
by: Anand S. Bhagwat, et al.
Published: (2016-04-01)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
by: Zhi-Qiang Wang, et al.
Published: (2023-11-01)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
by: Lori, L, et al.
Published: (2016)

BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells
by: Jingjun Li, et al.
Published: (2016-09-01)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
by: Laura Lori, et al.
Published: (2016-01-01)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
by: Hay, D, et al.
Published: (2013)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
by: Elisa Funck-Brentano, et al.
Published: (2021-01-01)

Promiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
by: Picaud, S, et al.
Published: (2016)

Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains
by: Zhicheng Shao, et al.
Published: (2016-09-01)

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
by: Timothy J. Stuhlmiller, et al.
Published: (2015-04-01)

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
by: Mengjun Zhong, et al.
Published: (2022-08-01)

Chemical probes and inhibitors of bromodomains outside the BET family
by: Moustakim, M, et al.
Published: (2016)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
by: Allison C. Ostriker, et al.
Published: (2015-11-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
by: Brown, Jonathan D., et al.
Published: (2018)

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1
by: Meropi Bagka, et al.
Published: (2023-07-01)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
by: Jennings, L, et al.
Published: (2018)

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
by: Shane D. Falcinelli, et al.
Published: (2022-04-01)

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
by: Mengjun Zhong, et al.
Published: (2022-08-01)